BRPI0906504A2 - Métodos para otimizar o tratamento de doenças proliferativas por receptor kit de tirosina quinase com imatinibe - Google Patents

Métodos para otimizar o tratamento de doenças proliferativas por receptor kit de tirosina quinase com imatinibe

Info

Publication number
BRPI0906504A2
BRPI0906504A2 BRPI0906504-0A BRPI0906504A BRPI0906504A2 BR PI0906504 A2 BRPI0906504 A2 BR PI0906504A2 BR PI0906504 A BRPI0906504 A BR PI0906504A BR PI0906504 A2 BRPI0906504 A2 BR PI0906504A2
Authority
BR
Brazil
Prior art keywords
imatinib
methods
tyrosine kinase
receptor tyrosine
proliferative diseases
Prior art date
Application number
BRPI0906504-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yanfeng Wang
Elisabeth Wehrle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0906504(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0906504A2 publication Critical patent/BRPI0906504A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0906504-0A 2008-01-23 2009-01-21 Métodos para otimizar o tratamento de doenças proliferativas por receptor kit de tirosina quinase com imatinibe BRPI0906504A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Publications (1)

Publication Number Publication Date
BRPI0906504A2 true BRPI0906504A2 (pt) 2015-07-14

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906504-0A BRPI0906504A2 (pt) 2008-01-23 2009-01-21 Métodos para otimizar o tratamento de doenças proliferativas por receptor kit de tirosina quinase com imatinibe

Country Status (14)

Country Link
US (3) US20100298338A1 (https=)
EP (1) EP2237783B1 (https=)
JP (2) JP5936821B2 (https=)
KR (1) KR101579993B1 (https=)
CN (1) CN101951910B (https=)
AU (1) AU2009206566A1 (https=)
BR (1) BRPI0906504A2 (https=)
CA (1) CA2712087A1 (https=)
ES (1) ES2526537T3 (https=)
MX (1) MX2010008103A (https=)
PL (1) PL2237783T3 (https=)
PT (1) PT2237783E (https=)
RU (1) RU2537223C2 (https=)
WO (1) WO2009094360A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
RU2362562C2 (ru) * 2003-11-18 2009-07-27 Новартис Аг Ингибиторы мутантной формы киназы kit
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2008036792A2 (en) * 2006-09-22 2008-03-27 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
NZ577320A (en) 2006-11-07 2012-01-12 Novartis Ag CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide

Also Published As

Publication number Publication date
JP5881671B2 (ja) 2016-03-09
KR101579993B1 (ko) 2015-12-23
RU2537223C2 (ru) 2014-12-27
JP2011510086A (ja) 2011-03-31
EP2237783B1 (en) 2014-11-19
US9763944B2 (en) 2017-09-19
CN101951910A (zh) 2011-01-19
US20160045501A1 (en) 2016-02-18
EP2237783A1 (en) 2010-10-13
AU2009206566A1 (en) 2009-07-30
WO2009094360A1 (en) 2009-07-30
PT2237783E (pt) 2014-12-23
ES2526537T3 (es) 2015-01-13
US20100298338A1 (en) 2010-11-25
CA2712087A1 (en) 2009-07-30
US20170035757A1 (en) 2017-02-09
MX2010008103A (es) 2010-08-23
RU2010134916A (ru) 2012-02-27
JP5936821B2 (ja) 2016-06-22
JP2014094946A (ja) 2014-05-22
CN101951910B (zh) 2013-07-17
PL2237783T3 (pl) 2015-04-30
KR20100105778A (ko) 2010-09-29

Similar Documents

Publication Publication Date Title
IL283038A (en) Processes for preparing jak inhibitors and related intermediate compounds
HUS2100050I1 (hu) IL-6 receptor elleni javított antitest molekula
IL280173A (en) Inhibitors of brutons tyrosine kinase
BRPI0716981A2 (pt) Inibidores de cinase úteis para o tratamento de doenças proliferativas
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BR112012007300A2 (pt) derivador de pirimidina como inibidores proteína tirosina cinase 2
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
HUE058231T2 (hu) Eszköz gastrooesophagealis reflux betegség kezelésére
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BR112012004718A2 (pt) compostos como moduladores de tirosina quinase
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
EP1978958A4 (en) RET tyrosine kinase Inhibition
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
EP2694486A4 (en) SUBSTITUTED N- (3- (PYRIMIDIN-4-YL-) PHENYL-) ACRYLAMIDE ANALOGUE AS TYROSINE RECEPTOR KINASE BTK INHIBITORS
BRPI0921156A2 (pt) inibidores de pi3k/mtor quinase
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
EP2515657A4 (en) Tyrosine kinase inhibitor
BRPI1008920A2 (pt) Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2550 DE 19-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.